Among the agents able to reduce MMP2 levels, particular attention should be given to the drug thalidomide, a potent anti-inflammatory agent that has shown promising results both in preclinical and clinical ALS studies (Kiaei et al. 2006; Stommel et al. 2009). The gene discussed is MMP2; the disease is amyotrophic lateral sclerosis.